Physiopathological modulators of amyloid aggregation and novel pharmacological approaches in Alzheimer's disease

Physiopathological modulators of amyloid aggregation and novel pharmacological approaches in Alzheimer's disease

The biological mechanisms underlying the neuropathology of Alzheimer's disease (AD) are complex, as several factors likely contribute to the development of the disease. Therefore, it is not surprising that a number of different possible therapeutic approaches addressing distinct aspects of this...

Full description

Bibliographic Details
Main Authors:	DEFELICE FERNANDA G., FERREIRA SÉRGIO T.
Format:	Article
Language:	English
Published:	Academia Brasileira de Ciências 2002-01-01
Series:	Anais da Academia Brasileira de Ciências
Subjects:	Alzheimer's disease Abeta peptide aggregation neurotoxicity physiopathological modulators
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652002000200006

Similar Items

The Roles of Lipid and Glucose Metabolism in Modulation of β-Amyloid, Tau, and Neurodegeneration in the Pathogenesis of Alzheimer disease
by: Naoyuki eSato, et al.
Published: (2015-10-01)

CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease
by: Vasileios Papaliagkas, et al.
Published: (2023-05-01)

Abstract P-34: The Regulation of Amyloid Proteins Aggregation by Adjacent Domains
by: Anastasia V. Grizel, et al.
Published: (2019-06-01)

Rapid Conversion of Amyloid-Beta 1-40 Oligomers to Mature Fibrils through a Self-Catalytic Bimolecular Process
by: Bertrand Morel, et al.
Published: (2021-06-01)

Possible Modification of Alzheimer Disease by Statins in Midlife: Interactions with Genetic and Non-Genetic Risk Factors
by: Mitsuru eShinohara, et al.
Published: (2014-04-01)

Opposite changes in APP processing and human Aβ levels in rats carrying either a protective or a pathogenic APP mutation
by: Marc D Tambini, et al.
Published: (2020-02-01)

2015: which new directions for Alzheimer’s disease?
by: Xénia eLATYPOVA, et al.
Published: (2014-12-01)

Rapid, Refined, and Robust Method for Expression, Purification, and Characterization of Recombinant Human Amyloid beta 1-42
by: Priya Prakash, et al.
Published: (2019-06-01)

Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer's disease
by: Lambracht-Washington D, et al.
Published: (2013-08-01)

Clinical effects of novel susceptibility genes for beta-amyloid: a gene-based association study in the Korean population
by: Bo-Hyun Kim, et al.
Published: (2023-10-01)

Study of Histopathological Lesions in CA1 of the Hippocampus after Injection of Beta-Amyloid in a Rat Model of Alzheimer’s Disease
by: SM Hoseini,, et al.
Published: (2012-07-01)

Somatostatin binds to the human amyloid β peptide and favors the formation of distinct oligomers
by: Hansen Wang, et al.
Published: (2017-06-01)

Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus
by: Tony Valente, et al.
Published: (2010-01-01)

Anti-Amyloid-β Monoclonal Antibodies: Recent Therapeutic Strategies for Alzheimer’s Disease
by: Maria Teresa Cruz, et al.
Published: (2022-03-01)

AMBAR, an Encouraging Alzheimer's Trial That Raises Questions
by: David A. Loeffler
Published: (2020-05-01)

Microglia in Alzheimer’s Disease: Activated, Dysfunctional or Degenerative
by: Victoria Navarro, et al.
Published: (2018-05-01)

New Evidence on a Distinction between Aβ40 and Aβ42 Amyloids: Thioflavin T Binding Modes, Clustering Tendency, Degradation Resistance, and Cross-Seeding
by: Anna I. Sulatskaya, et al.
Published: (2022-05-01)

Advance of physiopathologic mechanism and treatment of melasma
by: Na ZHOU, et al.
Published: (2022-04-01)

The location and trafficking routes of the neuronal retromer and its role in amyloid precursor protein transport
by: Akhil Bhalla, et al.
Published: (2012-07-01)

Exosomal Aβ-Binding Proteins Identified by “In Silico” Analysis Represent Putative Blood-Derived Biomarker Candidates for Alzheimer´s Disease
by: Tânia Soares Martins, et al.
Published: (2021-04-01)

Design, Synthesis, and Validation of a Novel [<sup>11</sup>C]Promethazine PET Probe for Imaging Abeta Using Autoradiography
by: Clayton A. Whitmore, et al.
Published: (2021-04-01)

Axonal generation of amyloid-β from palmitoylated APP in mitochondria-associated endoplasmic reticulum membranes
by: Raja Bhattacharyya, et al.
Published: (2021-05-01)

ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease
by: Liana G. Apostolova, et al.
Published: (2014-01-01)

ChatGPT Performances in Explanation of Physiopathology by Example
by: Alexandra Ina BULBOACĂ, et al.
Published: (2023-09-01)

White matter injury, cholesterol dysmetabolism, and APP/Abeta dysmetabolism interact to produce Alzheimer’s disease (AD) neuropathology: A hypothesis and review
by: Frank R. Sharp, et al.
Published: (2023-02-01)

Expression of endogenous mouse APP modulates β-amyloid deposition in hAPP-transgenic mice
by: Johannes Steffen, et al.
Published: (2017-06-01)

Alternative neural circuitry that might be impaired in the development of Alzheimer disease
by: Jesus eAvila, et al.
Published: (2015-04-01)

Brain Region-Specific Differences in Amyloid-β Plaque Composition in 5XFAD Mice
by: Angelika Sabine Bader, et al.
Published: (2023-04-01)

Pharmacological Inhibition of Amyloidogenic APP Processing and Knock-Down of APP in Primary Human Macrophages Impairs the Secretion of Cytokines
by: Philipp Spitzer, et al.
Published: (2020-09-01)

ApoE transiently regulates hippocampus amyloid‐beta deposition to stable learning and memory ability in adult rats exposed in sevoflurane
by: Shan Xu, et al.
Published: (2021-06-01)

Y682 mutation of amyloid precursor protein promotes endo-lysosomal dysfunction by disrupting APP-SorLA interaction
by: Luca Rosario La Rosa, et al.
Published: (2015-04-01)

Physiopathology and diagnosis of cardiotoxicity in patients submitted to chemotherapy treatment
by: Filipe C. Marmelo, et al.
Published: (2019-02-01)

Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer’s disease
by: David L. Brody, et al.
Published: (2017-08-01)

Naphthoquinone-tyrptophan reduces neurotoxic Aβ*56 levels and improves cognition in Alzheimer's disease animal model
by: R. Scherzer-Attali, et al.
Published: (2012-06-01)

Designed Cell-Penetrating Peptide Inhibitors of Amyloid-beta Aggregation and Cytotoxicity
by: Anja Henning-Knechtel, et al.
Published: (2020-02-01)

The Early Events That Initiate β-Amyloid Aggregation in Alzheimer’s Disease
by: Xingyu Zhang, et al.
Published: (2018-11-01)

The Changing Face of Inflammatory Bowel Disease: Etiology, Physiopathology, Epidemiology
by: Giovanni Clemente Actis
Published: (2016-03-01)

Modern pharmacological models of Alzheimer’s disease
by: V. V. Kolobov, et al.
Published: (2017-02-01)

Pharmacological Potential of Cilostazol for Alzheimer’s Disease
by: Kenjiro Ono, et al.
Published: (2019-05-01)

Modulation of β-amyloid aggregation by graphene quantum dots
by: Changliang Liu, et al.
Published: (2019-06-01)